Today's Trend
Larimar Therapeutics, Inc. (NASDAQ: LRMR) — The stock is down after heavy trading. The primary near-term driver is a company-led equity raise that will add material new supply; that dilution risk appears to have outweighed several bullish analyst actions and unusual options activity that supported the stock earlier in the session.
- Lifesci Capital upgraded LRMR to a "Strong-Buy" and published Q4 2025 and FY2025 EPS estimates (Q4: ($0.41); FY2025: ($1.70)), signaling analyst confidence in the company’s outlook and supporting demand for the shares. MarketBeat Lifesci Note
- Citigroup raised its price target to $14 (buy), and Wedbush reaffirmed an outperform rating with an $11 target — both represent substantial upside vs. the current level and underpin bullish analyst sentiment. Benzinga
- Unusually large call-option activity occurred (several thousand calls bought), suggesting short-term bullish positioning by traders and contributing to intraday spikes before the equity raise announcement. (No direct article link provided)
- Coverage and commentary explaining the intraday rally were published (coverage noted a ~22% intraday rise before the selloff), which can attract momentum buyers and increased attention. AAII Article
- The company initially announced a proposed $75M underwritten offering (preliminary press release) — this first filing signaled capital raise intent before the deal was upsized. GlobeNewswire - Proposed Offering
- Larimar priced an upsized underwritten public offering of 20,000,000 shares at $5.00 per share (gross proceeds ~$100M) and granted a 30-day option for an additional 3,000,000 shares — direct dilution and increased share supply are the main catalysts pressuring the stock. GlobeNewswire - Priced Offering
Implication for investors: the equity raise materially increases dilution risk in the near term and is the dominant negative driver. Offsetting positives include analyst upgrades, higher price targets and bullish options activity, which suggest continued investor interest if the company’s clinical progress and cash runway improve post-offering. Monitor final close of the offering, changes in share count, and any use-of-proceeds guidance that could alter the dilution vs. growth trade-off.